These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Quinpramine: revival of old anti-inflammatory principles in multiple sclerosis? Haghikia A; Gold R Exp Neurol; 2009 Jun; 217(2):240-1. PubMed ID: 19361499 [No Abstract] [Full Text] [Related]
43. Experimental autoimmune demyelination. Chronic relapsing models and their therapeutic implications for multiple sclerosis. Raine CS; Traugott U Ann N Y Acad Sci; 1984; 436():33-51. PubMed ID: 6085228 [No Abstract] [Full Text] [Related]
44. HLA class II transgenic mice as models of human diseases. Taneja V; David CS Immunol Rev; 1999 Jun; 169():67-79. PubMed ID: 10450509 [TBL] [Abstract][Full Text] [Related]
45. Monocyte/macrophage initiation of organ-specific autoimmunity: the ultimate 'bystander' hypothesis? Stoy NS Med Hypotheses; 2002 Apr; 58(4):312-26. PubMed ID: 12027526 [TBL] [Abstract][Full Text] [Related]
46. High-dose immunosuppressive therapy for rheumatoid arthritis: some answers, more questions. McSweeney PA; Furst DE; West SG Arthritis Rheum; 1999 Nov; 42(11):2269-74. PubMed ID: 10555019 [No Abstract] [Full Text] [Related]
48. CTRP6 is an endogenous complement regulator that can effectively treat induced arthritis. Murayama MA; Kakuta S; Inoue A; Umeda N; Yonezawa T; Maruhashi T; Tateishi K; Ishigame H; Yabe R; Ikeda S; Seno A; Chi HH; Hashiguchi Y; Kurata R; Tada T; Kubo S; Sato N; Liu Y; Hattori M; Saijo S; Matsushita M; Fujita T; Sumida T; Iwakura Y Nat Commun; 2015 Sep; 6():8483. PubMed ID: 26404464 [TBL] [Abstract][Full Text] [Related]
49. T lymphocyte clones and experimental autoimmune diseases. Cohen IR Behring Inst Mitt; 1985 Aug; (77):88-92. PubMed ID: 2417586 [TBL] [Abstract][Full Text] [Related]
50. Modelling of multiple sclerosis: lessons learned in a non-human primate. 't Hart BA; Laman JD; Bauer J; Blezer E; van Kooyk Y; Hintzen RQ Lancet Neurol; 2004 Oct; 3(10):588-97. PubMed ID: 15380155 [TBL] [Abstract][Full Text] [Related]
51. Genetic control of tolerance to type II collagen and development of arthritis in an autologous collagen-induced arthritis model. Bäcklund J; Nandakumar KS; Bockermann R; Mori L; Holmdahl R J Immunol; 2003 Oct; 171(7):3493-9. PubMed ID: 14500645 [TBL] [Abstract][Full Text] [Related]
52. Oral tolerance in the control of experimental models of autoimmune disease. Staines NA; Harper N Z Rheumatol; 1995; 54(3):145-54. PubMed ID: 7660685 [TBL] [Abstract][Full Text] [Related]
53. The immunopathogenesis and immunogenetics of rheumatoid arthritis. van Eden W; de Vries RR Br J Rheumatol; 1989; 28 Suppl 1():51-3; discussion 69-71. PubMed ID: 2684318 [No Abstract] [Full Text] [Related]
54. Type I interferon in organ-targeted autoimmune and inflammatory diseases. Crow MK Arthritis Res Ther; 2010; 12 Suppl 1(Suppl 1):S5. PubMed ID: 21303493 [TBL] [Abstract][Full Text] [Related]
55. Arthritis in MRL/LPR mice and in collagen II sensitized DBA-1 mice and their use in pharmacology. Rordorf C; Pataki A; Nogues V; Schlager F; Feige U; Glatt M Int J Tissue React; 1987; 9(4):341-7. PubMed ID: 3623829 [TBL] [Abstract][Full Text] [Related]
56. New findings and old controversies in the research of multiple sclerosis and its model experimental autoimmune encephalomyelitis. Aharoni R Expert Rev Clin Immunol; 2013 May; 9(5):423-40. PubMed ID: 23634737 [TBL] [Abstract][Full Text] [Related]
57. Effects of orally administered rapamycin in animal models of arthritis and other autoimmune diseases. Carlson RP; Baeder WL; Caccese RG; Warner LM; Sehgal SN Ann N Y Acad Sci; 1993 Jun; 685():86-113. PubMed ID: 8363289 [No Abstract] [Full Text] [Related]